Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors

Multiple therapeutic agents have been developed to target the phosphatidylinositol 3-kinase (PI3K) signaling pathway, which is frequently dysregulated in cancer promoting tumor growth and survival. These include pan PI3K inhibitors, which target class Ia PI3K isoforms and have largely shown limited...

Descripción completa

Detalles Bibliográficos
Autores principales: Rewcastle, Gordon W, Kolekar, Sharada, Buchanan, Christina M, Gamage, Swarna A, Giddens, Anna C, Tsang, Kit Y, Kendall, Jackie D, Singh, Ripudaman, Lee, Woo-Jeong, Smith, Greg C, Han, Weiping, Matthews, David J, Denny, William A, Shepherd, Peter R, Jamieson, Stephen M.F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564600/
https://www.ncbi.nlm.nih.gov/pubmed/28537878
http://dx.doi.org/10.18632/oncotarget.17730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564600/
https://www.ncbi.nlm.nih.gov/pubmed/28537878
http://dx.doi.org/10.18632/oncotarget.17730

Ejemplares similares